Game On: Revance Therapeutics Initiates Phase 3 Trial of Topical Botox
Will Revance's RT001 be the first topically neurotoxin treatment?
Will Revance's RT001 be the first topically neurotoxin treatment?
FDA approves RHA Redensity Eye for correction of moderate to severe tissue volume deficiencies in the infraorbital region in adults ages 22 and older.
A UK clinical study will evaluate Spectral AI’s DeepView System in anatomically complex burn areas, with a burns and plastic surgeon leading the first study site.
Revance Therapeutics Inc has established its field force and will begin introducing its aesthetics portfolio, including the RHA Collection of dermal fillers, hyaluronic acid, and the HintMD financial technology (fintech) platform, in the United States in September, it announces.
Read MoreRevance Therapeutics Incannounces results for two Phase 2a open-label, dose escalation studies of its investigational drug candidate DaxibotulinumtoxinA for Injection in the treatment of dynamic forehead lines (FHL) following glabellar (frown) line injections and lateral canthal lines (LCL), commonly known as crow’s feet.
Read MoreRevance Therapeutics Inc and Mylan NV announce Mylan’s decision to move forward with a development plan, under a 351(k) pathway, for a proposed biosimilar to BOTOX and BOTOX Cosmetic (onabotulinumtoxinA), according to a media release.
Read MoreRevance Therapeutics Inc, a Newark, Calif-based developer of neuromodulators for the treatment of aesthetic and therapeutic conditions, announces two pieces of company news regarding RT002.
Read MoreJUVEDERM ULTRA XC for lips and Coolscupting’s new Coolmini for the double chin are among November’s “Hot Stuff.”
Read More